Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2006

View Archived Issues

SuperGen to acquire Montigen Pharmaceuticals

Pharmos completes phase I study for cannabinor

CytRx to transfer RNAi therapeutics to new subsidiary

Rigel receives milestone payment from Merck ubiquitin ligase collaboration

Curcumin plus phenethyl isothiocyanate active against prostate cancer in vivo

H5N1 Avian influenza virus vaccine effective in mice and chickens

Albany Molecular Research to acquire ComGenex

IGFR inhibition shows promise for malignant mesothelioma

New D3R antagonist prevents negative symptoms of schizophrenia

New agents for immunological disorders imparted in recent Taisho patent

Recent patents describe new therapeutic agents for anxiety, depression etc.

Novel agents imparted for the treatment of inflammatory disorders

Shionogi describes new antiobesity agents in patent literature

CombinatoRx and Fovea to develop novel ophthalmic therapeutics

New phase I/II study for ZIO-101 in advanced myeloma

Thiovir active against influenza A virus in preclinical studies

Ardana holds pre-IND meeting with FDA for testosterone cream

Pharmexa files first application for phase III PrimoVax trial

Nastech and P&G collaborate on nasal PTH1-34

TP-508 promotes cartilage repair via activation of ERK1/2 MAPK

New respiratory agents highlighted in patent literature

Symphogen and Biovitrum to codevelop and commercialize SYM-001

Zalypsis to enter clinical testing in U.S.

LY-2275796 enters clinical trials in cancer patients

CONRAD and Cellegy sign agreement for microbicide R&D

Clarinex-D 12 Hour approved for seasonal allergic rhinitis

EMEA accepts for review Genasense MAA in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...